Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebif vs Avonex or Copaxone in RRMS
NCT00101959Phase 4Withdrawn
- Sponsor
- EMD Serono
- Start
- Nov 2004
- Modality
- Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of interferon beta in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by EMD Serono. Primary endpoint: Time to worsening to a medium level of concern as defined by the Canadian Multiple Sclerosis Working Group (CMSWG) treatment optimization recommendations at 2 years. Planned start Nov 2004; status: withdrawn.
02
Drugs
interferon beta
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00101959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101959.